Mirae Asset Global ETFs Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Buy	138,083 +6,923	+5%	+$62.6K	﹤0.01%	1467
2026 Q1	$1.25M	Buy	131,160 +11,593	+10%	+$90K	﹤0.01%	1413
2025 Q4	$929K	Buy	119,567 +3,366	+3%	+$24.3K	﹤0.01%	1562
2025 Q3	$881K	Sell	116,201 -13,303	-10%	-$111K	﹤0.01%	1558
2025 Q2	$1.17M	Sell	129,504 -5,810	-4%	-$54.1K	﹤0.01%	1376
2025 Q1	$1.02M	Buy	135,314 +8,517	+7%	+$68.7K	﹤0.01%	1488
2024 Q4	$954K	Sell	126,797 -929	-0.7%	-$7.05K	﹤0.01%	1571
2024 Q3	$971K	Buy	127,726 +14,199	+13%	+$108K	﹤0.01%	1555
2024 Q2	$700K	Buy	+113,527	New	+$626K	﹤0.01%	1650

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's BCRX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its BioCryst Pharmaceuticals (BCRX) stake by 5.3% in Q2 2026, buying an estimated $62.6K and bringing the position to 138,083 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

Mirae Asset Global ETFs Holdings first reported a position in BCRX in Q2 2024 and has held it in 9 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 138,083 shares of BioCryst Pharmaceuticals worth $1.37M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 6,923 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $62.6K.
BioCryst Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1467 holding.
Mirae Asset Global ETFs Holdings first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.